February 23, 2009-Daiichi Sankyo Company, Limited and Eli Lilly and Company announced today that the European Commission has granted marketing authorization for EFIENT(pronounced Ef-ee-ent) (prasugrel) for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI).
The details can be read here.
No comments:
Post a Comment